News and Announcements
EDITORIAL
Tumor immunotherapy: A crucial area for immediate focus
Show Less
1 College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin,
China
2 Famous Traditional Chinese Medicine Hall, Tianjin Hospital of ITCWM Nankai Hospital, Tianjin,
China
3 Tianjin Key Laboratory of Modern Chinese Medicine Theory of Innovation and Application, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin,
China
EJMO, 025120059 https://doi.org/10.36922/EJMO025120059
Submitted: 18 March 2025 | Accepted: 31 March 2025 | Published: 16 April 2025
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Conflict of interest
Xianbin Kong is an Editorial Board Member of this journal but was not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. Separately, other authors declared that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
References
- Yildiz B, Acar R. Immunotherapy in geriatric patients with advanced cancer. EJMO. 2020;4(3):209-214. doi: 10.14744/ejmo.2020.44446
- Esfahani K, Meti N, Miller WH Jr., Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019;191(2):E40-E46. doi: 10.1503/cmaj.180870
- Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707-723. doi: 10.1016/j.cell.2017.01.017
- Wang Y, Deng W, Li N, et al. Combining immunotherapy and radiotherapy for cancer treatment: Current challenges and future directions. Front Pharmacol. 2018;9:185. doi: 10.3389/fphar.2018.00185
- Wang M, Yu F, Zhang Y. Present and future of cancer nano-immunotherapy: Opportunities, obstacles and challenges. Mol Cancer. 2025;24(1):26. doi: 10.1186/s12943-024-02214-5